Alzheimer’s trial brings at-risk patients hope for the future, but new doubts in the present - The Globe and Mail
Tyson Haller, at risk for Alzheimer's due to family history, participates in the AHEAD 3-45 study testing lecanemab, a drug aiming to prevent Alzheimer's by targeting amyloid plaques. Despite modest success in slowing disease progression, challenges remain, including high costs and side effects. The study represents hope for early intervention, with ongoing trials and debates on diagnosis and treatment efficacy.
Reference News
Tyson Haller, at risk for Alzheimer's due to family history, participates in the AHEAD 3-45 study testing lecanemab, a drug aiming to prevent Alzheimer's by targeting amyloid plaques. Despite modest success in slowing disease progression, challenges remain, including high costs and side effects. The study represents hope for early intervention, with ongoing trials and debates on diagnosis and treatment efficacy.